Novartis allies with Conatus in $722mm liver disease R&D pact; later terminated
Novartis AG and Conatus Pharmaceuticals Inc. will collaborate on the development and commercialization of Conatus' emricasan (IDN6556) alone for nonalcoholic steatohepatitis (NASH) and in combination with other farnesoid X receptor (FXR) agonists the Big Pharma has in its pipeline for NASH and other chronic liver diseases.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.